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Early treatment-induced improvement of negative symptoms
predicts cognitive functioning in treatment-naive first episode
schizophrenia: a 2-year followup
Abstract
Studying neuroleptic-naive first episode schizophrenia is a strategy for investigating clinical and
neuropsychological abnormalities at a very early phase of the disease without confounding influences of
illness duration and medication effects. We examined the clinical and neuropsychological time course
over 2 years in 32 neuroleptic-naive first episode patients (20 males, 12 females) and 21 healthy
individuals with similar sociodemographic characteristics. Early treatment-induced reduction of
negative symptoms predicted superior cognitive performance throughout followup in the domains of
verbal fluency, attention, and non-verbal learning and memory. There were no associations between
psychotic or disorganized symptoms and cognitive variables. These findings suggest an important
relationship between treatment efficacy of antipsychotic medication and the longer term course of
cognitive deficits in schizophrenia.
Early Treatment-Induced Improvement of
Negative Symptoms Predicts Cognitive
Functioning in Treatment-Naive First Episode
Schizophrenia: A 2-Year Followup
by Daniel Schuepbach, S. Kristian Hill, Richard D. Sanders, Daniel Hell,
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Abstract
Studying neuroleptic-naive first episode schizophrenia
is a strategy for investigating clinical and neuropsy-
chological abnormalities at a very early phase of the
disease without confounding influences of illness dura-
tion and medication effects. We examined the clinical
and neuropsychological time course over 2 years in 32
neuroleptic-naive first episode patients (20 males, 12
females) and 21 healthy individuals with similar
sociodemographic characteristics. Early treatment-
induced reduction of negative symptoms predicted
superior cognitive performance throughout followup
in the domains of verbal fluency, attention, and non-
verbal learning and memory. There were no associa-
tions between psychotic or disorganized symptoms and
cognitive variables. These findings suggest an impor-
tant relationship between treatment efficacy of
antipsychotic medication and the longer term course of
cognitive deficits in schizophrenia.
Keywords: Schizophrenia, followup, verbal mem-
ory, learning, neuropsychology.
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Schizophrenia is a severe mental illness that has interested
clinicians and researchers for more than a century (Bleuler
1911; Kraepelin 1919), and disturbances of thinking were
recognized very early as one of the disease's core features.
Cognitive deficits have been described in schizophrenia in
general (for review, see Heinrichs and Zakzanis 1998;
Rund and Borg 1999), and more recently as occurring in
first episode schizophrenia close to the time of illness
onset (Sweeney et al. 1991; Bilder et al. 1992; Hoff et al.
1992; Saykin et al. 1994; Censits et al. 1997; Mohamed et
al. 1999; Bilder et al. 2000). These deficits involve multi-
ple areas of functioning, such as complex language func-
tions, verbal learning and memory, attention, executive
functions, visual memory, and motor speed. Censits et al.
(1997) and Hoff et al. (1999) demonstrated a stable pat-
tern of cognitive dysfunction over time periods from 1 to
4 years, and associations between symptoms and cogni-
tive performance. Censits et al. (1997) showed broad-
based correlations between negative symptom severity
and impairments in cognition. These associations were
evident for domains of attention, language, abstraction,
verbal memory, and spatial memory, and spatial and sen-
sory abilities. In large studies on first episode schizophre-
nia, the Hillside group published several important reports
addressing clinical and neuropsychological measures at
followup (Lieberman et al. 1992; Robinson et al. 1999).
Robinson et al. (1999) evaluated a considerable number of
predictors of treatment response in this patient group and
found that, apart from sociodemographic and premorbid
factors, measures of attention predicted treatment
response. Another group found an association between
treatment response and negative symptoms in first episode
schizophrenia (Scottish Schizophrenia Research Group
1987). Finally, Bilder et al. (2000) investigated a large
sample of first episode patients in a cross-sectional design
and found only small-to-medium effect sizes when esti-
mating relationships between clinical and neuropsycho-
logical measures. Of interest, these authors observed
smaller associations between those variables at study
entry than they did between those variables close to the
time of neuropsychological assessment, when patients
were clinically stable. Mainly negative symptoms had an
inverse association with memory, attention, and global
neuropsychological performance.
Hoff et al. (1999) used a multiple-time-point design
to characterize first episode schizophrenia from a clinical,
neuropsychological, and neuroradiological perspective,
yielding valuable information regarding possible change
of those parameters over time. Cognitive deficits were evi-
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dent at initial hospitalization, with little change during the
observation period.
In recent years there has been great interest in the
prediction of functional outcome in schizophrenia. Green
et al. (2000) and Green and Nuechterlein (1999) empha-
sized the role of cognitive deficits (e.g., verbal memory)
for functional outcome, suggesting a closer linkage to
fundamental aspects of the illness rather than its immedi-
ate symptomatic expression. In a recently published study
from our group with neuroleptic-naive schizophrenia
patients (Schuepbach et al. 2002), early treatment-induced
reduction in negative symptoms was associated with
enhanced cognitive functions after 1 month of treatment,
especially in the domains of verbal fluency and attention.
Based on these results, we were particularly inter-
ested in addressing the following predictions: (1) that
early treatment-induced reduction in negative symptoms
is associated with long-term cognitive outcome in first
episode schizophrenia, thus extending our findings on this
association in the period immediately following treatment
initiation; and (2) that because there is ample evidence
that cognitive functioning is a core feature of schizophre-
nia, early cognitive performance change is associated
with long-term symptom severity.
Methods
Subjects. Thirty-two neuroleptic-naive first episode psy-
chotic subjects were recruited who were initially diag-
nosed with schizophrenia or schizophreniform disorder
and later confirmed as having schizophrenia (n = 30) or
schizoaffective disorder (n = 2) according to DSM-IV
(APA 1994). Patient reports of prior treatment history
were confirmed by family members and treating physi-
cians. The diagnoses were based on the Structured
Clinical Interview for DSM-III-R or DSM-IV disorders
(SCID; Spitzer et al. 1987, 1994) and all other available
information, which was reviewed at a consensus diagnosis
meeting by senior investigators and clinical staff. Patients
interviewed with the SCID for DSM-III-R had their
responses reviewed to verify that they met DSM-IV diag-
nostic criteria for disorders of interest.
The focus of this report was on symptom and cogni-
tive performance change in patients with schizophrenia.
However, to estimate how neuropsychological perform-
ance (baseline/followup) differed between patients and
healthy subjects, a comparison group was included in this
study. Data presentation was restricted for the following
reasons: (1) to show an overall estimate of performance
difference at baseline assessment; (2) to demonstrate, on a
descriptive basis, the time course of selected cognitive
functions as compared with patients; and (3) to provide
information on consistency of neuropsychological tests in
healthy subjects, a relevant aspect in a longitudinal study.
The comparison group comprised 21 healthy individuals
recruited from the surrounding community. They had no
Axis I disorder by SCID interview. The comparison group
was selected to match the patient sample on age, sex, eth-
nicity, and parental socioeconomic status (Hollingshead
1975) (table 1). All subjects met the following criteria: (1)
age between 18 and 55 years; (2) no known systemic or
neurologic illness; (3) no prior treatment with electrocon-
vulsive shock therapy; (4) no history of head trauma with
loss of consciousness for more than 10 minutes; (5) no
lifetime history of substance dependence, or of substance
abuse in the 3 months preceding entry into the study; and
(6) no anticonvulsants or benzodiazepines for 1 month.
The study was approved by the Institutional Review
Board of the University of Pittsburgh. All participants
gave their written and witnessed informed consent to par-
ticipate in these studies. Twenty-four patients and 16
healthy controls of the current study were included in our
previous investigation on short-term clinical and neu-
ropsychological changes after treatment initiation
(Schuepbach et al. 2002). Some of these cases were lost to
followup and thus are not included in this report, and
additional cases were added since that manuscript was
submitted for publication.
Clinical Ratings. The Scale for the Assessment of
Negative Symptoms (SANS; Andreasen 1989) and the
Scale for the Assessment of Positive Symptoms (SAPS;
Andreasen 1990) were completed close to the time of the
neuropsychological evaluations without knowledge of the
findings from cognitive investigations. Similarly, neu-
ropsychological testing was done without knowledge of
clinical ratings. Symptom factors were generated as fol-
lows (Schuepbach et al. 2002): total SANS score (includ-
ing global ratings of affective flattening, alogia, avoli-
tion/apathy, attention, and anhedonia/asociality) was taken
as an index of negative symptoms; global SAPS ratings of
hallucinations and delusions were used as an index of
psychotic symptoms; and global SAPS ratings of bizarre
behavior and formal thought disorder were combined as
an index of disorganized symptoms. Additionally, we
included the depression item from the Brief Psychiatric
Rating Scale (Overall and Gorham 1962) in the analyses
to estimate depressive symptoms during the followup and
their relation to negative symptoms and cognition. Raters
achieved an intraclass correlation coefficient of at least
0.80 on the clinical rating instruments.
Neuropsychological Assessment. Neuropsychological
examination took place within 72 hours of clinical ratings.
Verbal learning and memory were assessed with the
California Verbal Learning Test (CVLT; Delis et al. 1983)
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Table 1. Sociodemographic and clinical characteristics of the study sample
Sociodemographic variables
Age (yrs)
Gender (male/female)
Race
Caucasian
African-American
Asian
Hispanic
Parental SES
Total education (yrs)
Word-reading ability
Patient's history
Age at onset of illness (yrs)
Duration of illness (yrs), median
(SE)
No. of psychiatrics
hospitalizations
Symptom severity at baseline
Psychotic symptoms
Disorganized symptoms
Negative symptoms
Average medication dose
antipsychotic (CPZE)
Patients on anticholinergics (%)1
Schizophrenia
patients (n = 32)
27.4 (8.2)
20/12
20
10
1
1
2.2(1.0)
15.1 (2.2)
101.2 (14.2)
25.3 (7.9)
1.0(0.69)
0.1 (0.3)
6.1 (2.6)
3.5 (2.0)
2.7 (0.6)
139.3(105.8)
23.44 (9.02)
Healthy individuals
(n = 21)
23.9 (5.6)
16/5
13
6
0
2
2.6(1.2)
14.3(3.6)
110.7(9.0)
NA
NA
NA
NA
NA
NA
NA
NA
x
2ort
1.85
1.09
1.60
1.13
0.92
2.95
P
ns
ns
ns
ns
ns
0.005
Note.—CPZE = chlorpromazine equivalent; NA = not applicable; ns = nonsignificant; parental SES = parents' socioeconomic status,
using the Hollingshead Scale; SE = standard error. Values are mean (standard deviation) if not indicated differently.
1
 Percentage of patients taking benztropine mesylate during followup.
using the following scores: total recall over all five learning
trials, short delay free and cued recall, long delay free and
cued recall, and recognition discriminability. Starting with
the initial CVLT form at baseline, the alternating form was
administered at 1-month followup, alternating with the ini-
tial form at subsequent assessment points. We introduced
this sequence after we commenced recruitment, so only 21
out of 32 schizophrenia patients and all healthy subjects
received the alternating forms of this test over the course of
followup. Language skills were assessed by verbal fluency
with the Controlled Word Association Test (Benton and
Hamsher 1983). Attention was assessed using the Digit
Span and Digit Symbol tests from the Wechsler Adult
Intelligence Scale-Revised (WAIS-R; Weschler 1981) and
the Trail Making Forms A and B (Reitan and Wolfson
1985). Visual perception and learning were assessed with
the Benton Judgment of Line Orientation Test (Benton
1975) and with the immediate and delayed visual memory
design reproduction of the Wechsler Memory
Scale-Revised (WMS-R; Wechsler 1987). Basic manual
psychomotor skills were assessed with the Finger Tapping
Test (Reitan and Wolfson 1985) and the Grooved Pegboard
Test (Klove 1963). Raw scores were converted to standard-
ized z scores, with performance of healthy subjects at base-
line set at 0 and standard deviation at 1. Scale scores were
inverted where appropriate, so that lower values always
represented lower performance.
In certain circumstances of longitudinal studies, cog-
nitive performance change is of interest. Therefore, the
calculation of neuropsychological change was carried out
with residualized scores in which variance related to base-
line performance of a defined task was partialed out of
scores obtained at followup. Residuals are defined as dif-
ferences between observed and predicted values of the
solution. By dividing those values by the standard error of
the estimate, standardized residuals were obtained. Where
appropriate, residualized scores were inverted, so that
lower values always represented less improvement in per-
formance. Average performance change scores within
each domain of functioning were computed to estimate
839
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overall performance change. Theoretical considerations of
this method are discussed in McSweeney et al. (1993) and
Sawrie (2002), and an example of residuals in longitudi-
nal data can be found in Piper et al. (1999). Because only
the last 21 patients recruited received alternating forms of
the CVLT at followup, analyses were separately carried
out for the full sample for all tests except the CVLT (all
32 patients), and separately for the CVLT, with analyses
restricted to the subset of subjects who had alternating
forms of the test administered throughout followup.
Medication. While all patients were neuroleptic-naive at
baseline assessments, antipsychotic agents were given
shortly thereafter to treat psychotic symptoms. The type
of antipsychotic agent and dosage were prescribed
according to the treating physician's judgment. The same
was true for anticholinergic medication. Initial antipsy-
chotic treatment comprised haloperidol (n - 13), risperi-
done (n = 17), loxapine (n - 1), and perphenazine (n = 1).
Anticholinergics were administered according to clinical
judgment based on extrapyramidal side effects. Average
antipsychotic dosage and the percentage of patients
receiving anticholinergics across all of the followup
assessments are given in table 1.
Followup Assessments, Missing Data. After study entry
at baseline, patients were reassessed after 1,6, 12, and 24
months. Seven out of 32 patients had no followup assess-
ments at year 2. Three of these patients were lost to fol-
lowup after year 1, and four had not yet reached the 2-
year followup endpoint. We did not detect significant
baseline differences of sociodemographic or clinical vari-
ables between these patients and the rest of the sample
(Mann-Whitney U test, p > 0.05). We therefore assumed a
random pattern of missing values and replaced missing
values to achieve maximum power and minimal bias in
the following way. Using evidence of Rund and Borg
(1999) and Hoff et al. (1999), we assumed a stable clini-
cal and neuropsychological pattern between followup
intervals of year 1 and 2 and extended the last available
data through to the year endpoint. Four patients had no
followup at 6 months, and two had no followup at 1 year.
For these missing values, we used the linear trend of
available data to predict missing values.
Statistical Analyses. The Kolmogorov-Smirnov test was
used to test for normality of distributions; non-normally
distributed data were transformed. Where transformations
were not appropriate, nonparametric procedures were used.
The mixed procedure, PROC MIXED (SAS Institute
Inc., Cary, NC), was used to confirm results of the general
linear model (GLM), because it can accommodate data
that are missing at random. Because findings of PROC
MIXED were largely the same as those with GLM, only
results of GLM are reported.
Results
Sociodemographic and clinical characteristics are summa-
rized in table 1. Severity of symptoms at baseline was
comparable to that in other studies in first episode schizo-
phrenia (Szymanski et al. 1996). Word-reading ability
(Wide-Range Achievement Test-Revised; Jastak and
Wilkinson 1984) was greater in healthy individuals (table
1). Consistency of raw scores across followup assess-
ments was examined, with Cronbach's coefficient alpha
showing a range from 0.80 to 0.96 in healthy subjects.
Time Course of Clinical Symptoms. Antipsychotic
treatment reduced symptoms over time. Significant reduc-
tions were seen for psychotic (f(31) = 7.08, p < 0.001),
disorganized (t(3l) = 5.54, p < 0.001), and negative
symptoms (f(31) = 3.73, p < 0.01) after 1 month (figure
1). No other significant changes were observed over the
followup period (p > 0.1). We calculated the relative
change between baseline and followup at 1 month as an
index of clinical response to antipsychotic medication
according to our recently published report (Schuepbach et
al. 2002). There was no significant association between
medication dose and age of onset with either clinical
symptoms or neuropsychological parameters.
Neuropsychological Deficits in Schizophrenia. There
was a significant overall difference in neuropsychological
performance at baseline between patients and healthy sub-
jects as revealed by a 2 (patients vs. healthy subjects) by
18 (all neuropsychological test data) multiple analysis of
variance (MANOVA; Wilks' lambda = 0.35, F(18,34) =
3.48, p < 0.01), and analyses including followup data sup-
ported a generally stable pattern of cognitive deficits over
time (data not shown).
Early Change of Clinical Symptoms and Its
Association With Cognitive Function. Based on find-
ings from our prior study indicating that reduction in neg-
ative symptoms is associated with better cognitive func-
tioning after acute treatment in first episode schizophrenia
(Schuepbach et al. 2002), this variable was used as a pre-
dictor of cognitive performance at followup:
1. A 2 (low vs. high early SANS improvers, split at the
group median of 13.33%) by 4 (all followup
intervals) by 12 (all tests excluding CVLT)
repeated measures MANOVA with residualized
scores as dependent measures showed a signifi-
cant effect of early negative symptom change on
cognitive functioning (F(l,30) = 7.53, p = 0.01).
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Figure 1. Time course of clinical symptoms from baseline until followup at 2 years
o
Eo
<U
SP
Psychotic symptoms
Negative symptoms
i — Disorganized symptoms
'p<0.01; *"p< 0.001
Univariate analyses indicated that those who
demonstrated more pronounced reduction in neg-
ative symptoms after acute treatment showed
better long-term performance in verbal fluency
(p < 0.01); WAIS-R Digit Symbol (p < 0.05);
WMS-R, visual reproduction, delayed (p <
0.001); and Grooved Pegboard of the nondomi-
nant hand (p < 0.05) (figure 2). There were no
significant relations between early improvement
in psychotic or disorganized symptoms and long-
term cognitive performance (p > 0.1). Because
dichotomizing the patient group may result in a
loss of information, additional correlational
analyses between different symptom measures
and average cognitive performance change
across all followup intervals are presented in
table 2. Similar to the findings reported in
another recent article of ours (Schuepbach et al.
2002), analyses with this partially overlapping
sample indicated that negative symptom reduc-
tion after acute treatment was significantly asso-
ciated with cognitive performance change during
that time period (data not shown).
2. We conducted analyses using early symptom change as
an independent measure in multiple regression
analyses with symptom severity at baseline as a
covariate and average cognitive performance
change at followup assessment of 2 years as a
dependent variable. Negative symptom change
was a significant predictor of cognitive perform-
ance excluding CVLT (R2 = 0.20, F(l,30) = 7.66,
standardized beta = 0.45, p - 0.01), and there
was no effect of baseline symptoms (p > 0.1)
(figure 3A). No other associations with clinical
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Figure 2. Time course of neuropsychological functions at foilowup assessments (residuaiized
scores)
A) Verbal fluency B) WAIS-R Digit Symbol
1.0 r:—rf-
0 1 6 12 18 240 1 6 12 18 24
C) WMS-R - delayed D) Grooved pegboard - nondominant hand
1.0 r 1.0 r-
- •— Low SANS improvers, n = 14
-•— High SANS improvers, n = 18
• + • Healthy controls, n = 21
Note.—SANS = Scale for the Assessment of Negative Symptoms; WAIS-R = Wechsler Adult Intelligence Scale-Revised; WMS-R =
Wechsler Memory Scale-Revised. On x-axis, breaks were inserted between 0 and 1 month to increase the readability of the figures.
Results of independent sample nests comparing low and high SANS improvers (split along the group median of 13.33%) are shown. For
comparison purposes, results of healthy subjects are also shown.
* p< 0.05; **p< 0.01
measures were significant (p > 0.1). Depression
was not a significant cofounder of the above-
mentioned associations between cognitive func-
tion and negative symptoms (p > 0.1).
Early Change of Cognitive Function and Symptom
Prediction. Correlation analysis between early average
cognitive performance change and average symptom
score at all foilowup intervals revealed significant inverse
associations between cognitive functions when analyses
were conducted excluding or including verbal learning
and memory performance and negative symptoms (p <
0.05) (table 3). Significant inverse correlations of individ-
ual tests with negative symptoms included verbal fluency
(p < 0.05); WMS-R, visual reproduction, delayed (p <
0.05); Trail Making Form A (p < 0.05); and CVLT short
delay free (p - 0.01) and long delay cued recall (p <
0.05). Early cognitive performance change excluding ver-
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Table 2. Correlations between clinical measures and average standardized neuropsychological
change scores (1-24 months of followup) in functioning from baseline, after treatment
Clinical symptoms
Average performance A
functions without CVLT Average performance A CVLT
Symptoms at baseline
Psychotic
Disorganized1
Negative
Symptom change at 1 mo2
Psychotic
Disorganized1
Negative
Symptom change at 24 mos2
Psychotic1
Disorganized1
Negative
Average symptom score2
Psychotic
Disorganized
Negative
0.05
-0.16
0.11
0.18
-0.02
0.49*
-0.13
-0.12
0.09
-0.20
-0.07
-0.18
-0.10
0.12
-0.29
0.12
0.29
0.44*
0.26
0.35
0.33
-0.19
-0.25
-0.56*
Note.—CVLT = California Verbal Learning Test (n = 21), except baseline (n = 32); functions without CVLT = functions excluding California
Verbal Learning Test {n = 32).
1
 Spearman's rho.
2
 Partial correlation, controlling for symptom severity at baseline.
*p<0.05;**p<0.01
bal learning and memory predicted negative symptom
severity at followup of 2 years only by tendency (figure
3B). No significant effects with psychotic and disorga-
nized symptoms were found (p > 0.05). Overall, these
results show an inverse association between measures of
early average cognitive performance change and negative
symptom severity at followup.
Discussion
This longitudinal study investigating parallels in clinical
and neuropsychological changes after treatment initiation
in first episode schizophrenia yielded several important
results. First, early treatment-induced change of negative
symptoms was associated with short- and long-term cog-
nitive outcome. Patients with greater reductions in nega-
tive symptoms over the first month of treatment showed
significantly better cognitive performance over followup
than other patients, particularly in the domains of verbal
fluency, attention, and nonverbal learning and memory.
Second, early cognitive performance change was signifi-
cantly associated with negative symptoms during the fol-
lowup period. Generally, cognitive deficits remained sta-
ble after treatment initiation as in other studies, and the
relation between negative symptom change with acute
therapy to cognitive ability persisted throughout the 2-
year followup period.
Our study population was antipsychotic-naive at
baseline, so the analyses we report were not confounded
by chronicity of illness or the sequelae of recent or long-
term treatment. With reference to our baseline assess-
ments, we observed little evidence for an association of
psychotic state with cognitive functioning, consistent with
findings from other reports (Bilder et al. 2000). There
have been few previous studies following neuroleptic-
naive first episode schizophrenia patients longitudinally
(vs. baseline/endpoint design) focusing on neuropsycho-
logical performance. Most previous neuropsychological
followup investigations on first episode or early-phase
schizophrenia had a baseline condition involving testing
patients taking medication (Hoff et al. 1999), had a base-
line/endpoint design (Censits et al. 1997), or had a combi-
nation of first episode and chronic patients (Censits et al.
1997).
Our observation that early treatment-induced reduc-
tions in negative symptoms were significantly associated
with cognitive function for up to 2 years is especially
important. It indicates that those patients who were able to
benefit from antipsychotic treatment early in their course
of illness in terms of negative symptom reduction had a
843
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Figure 3. (A) Early negative symptom change versus cognitive performance excluding verbal learning
and memory at followup of 2 years (R2 = 0.20, p = 0.01); (B) early cognitive performance change
excluding verbal learning and memory versus negative symptoms at followup of 2 years (R2 = 0.10,
p = 0.08)
A) B)
-2.0
-40 -20 0 20 40
Early SANS change (1 mo)
</2
<
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5
Early cognitive performance change (1 mo)
Note.—SANS = Scale for the Assessment of Negative Symptoms. Dashed lines indicate 95% confidence intervals.
Table 3. Correlations between averaged standardized neuropsychological variables and clinical
measures (1-24 months of followup) in functioning from baseline and after treatment
Average cognitive measures
Performance at baseline
Functions without CVLT
CVLT1
Performance change at 1 mo
Functions without CVLT
CVLT
Performance change at 24 mos
Functions without CVLT
CVLT
Average
psychotic
symptoms2
0.11
-0.33
-0.03
-0.31
-0.17
0.00
Average
disorganized
symptoms2
-0.16
-0.15
-0.29
-0.32
-0.02
-0.06
Average
negative
symptoms2
-0.33
-0.16
-0.42*
-0.50*
-0.20
-0.54*
Note.—CVLT = California Verbal Learning Test (n = 21), except baseline (n = 32); functions without CVLT = functions excluding California
Verbal Learning Test (n = 32).
1
 Spearman's rho.
2
 Partial correlation, controlling for symptom severity at baseline.
* p < 0.05; " p< 0.01
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superior long-term cognitive outcome. These findings
indicate that cognitive changes associated with short-
term, treatment-induced change of negative symptoms
can be still seen 2 years later and extend results from our
recently published study (Schuepbach et al. 2002) by
showing a persistence of these early treatment-related
cognitive changes in first episode schizophrenia. Until
now there have been no other reports that have systemat-
ically investigated this association. Bilder et al. (1991)
found an inverse association of reduction of negative
symptom ratings and improvement of neuropsychologi-
cal performance over 1 year. The results of our study
also lend support to the notion that early cognitive per-
formance change predicts average negative symptom
severity, and hence confirm widely accepted assump-
tions that cognitive deficits may represent a core feature
of the illness (Elvevag and Goldberg 2000). At baseline,
patients were psychotic, were unmedicated, and had
never taken antipsychotic medication. In accordance
with another report (Szymanski et al. 1996), reduction of
psychotic and disorganized symptoms was greater than
reduction of negative symptoms. Peralta et al. (2000)
investigated treatment-induced changes of negative
symptoms in neuroleptic-naive patients and suggested
that negative symptoms at this stage were mainly pri-
mary or illness related. Although negative symptoms at
baseline responded partially to antipsychotic treatment
in our study, patients varied in the degree of benefit they
received in this regard. These results are in agreement
with evidence that antipsychotic agents—typical (in
lower doses) (Seidman et al. 1993) and atypical medica-
tions (Kane et al. 1988; Chouinard et al. 1993)—reduce
negative symptoms. Goff and Evins (1998) reviewed a
large body of literature on negative symptoms in schizo-
phrenia and concluded that there might be a subgroup of
patients that are unlikely to respond to pharmacological
interventions.
From our study's findings, one could argue that the
initial improvement in negative symptom severity is
attributable to a state-related phenomenon, where patients
went from an untreated and psychotic state to a treated
and non- or less psychotic state. This happened during a
relatively short time period of 1 month. From these find-
ings, it may be concluded that change in negative symp-
toms plays an important role in the modulation of cogni-
tive performance in schizophrenia, and that a reduction in
negative symptoms may be an even more important target
for treatment than has been previously appreciated.
Although this study does not provide extensive analysis
on clinical and neuropsychological variables at baseline,
one might hypothesize that differences in early change
measures represent a neurobiological correlate of this ill-
ness at baseline.
An important psychopathological model linked to
concepts of negative symptoms deserves to be mentioned
in this regard: the deficit syndrome (Carpenter et al.
1988). This syndrome is defined by enduring negative
symptoms that are essentially unrelated to secondary
causes. While only approximately 10 percent of first
episode schizophrenia patients fulfill criteria of a deficit
syndrome (Fenton and McGlashan 1994), it is possible
that the patients we characterized who show low treat-
ment-induced improvement of negative symptoms linked
to neuropsychological deficits may be more likely to
develop or manifest this syndrome later in their illness.
Our findings further illustrate the importance of clarifying
the neurobiological basis of negative symptoms in schizo-
phrenia, which likely involves the frontal cortex, the lim-
bic system, the basal ganglia and temporal lobe structures,
and dysregulation of several neurotransmitter systems,
including dopamine, norepinephrine, glutamate, and sero-
tonin (for review, see Goff and Evins 1998).
Certain limitations of our study need to be consid-
ered. First, this was a naturalistic study where antipsy-
chotic treatment was administered according to the deci-
sion of treating physicians. It was therefore not possible to
draw definite inferences about differential medication
effects or dosage effects on clinical and neuropsychologi-
cal variables. Second, the sample size of groups was rela-
tively small; despite strategies to circumvent this draw-
back, further investigations with larger study groups are
necessary. Last, the study raises a number of questions
that need to be addressed regarding the neurobiological
basis of cognitive enhancement with antipsychotic treat-
ment, to move toward prescriptive selection of different
pharmacotherapies for schizophrenia based on their suit-
ability for particular patients and targeted change in clini-
cal status.
Conclusion
In this 2-year followup study with first episode antipsy-
chotic-naive schizophrenia patients, we observed signifi-
cant associations between early negative symptom change
and cognitive abilities over a 2-year followup as well as
an impact of early cognitive performance change on nega-
tive symptoms during that time period. To the best of our
knowledge, this is the first demonstration in neuroleptic-
naive first episode schizophrenia of a direct linkage
between, on the one hand, the early benefits of antipsy-
chotic medications in terms of reductions in negative
symptoms and, on the other, long-term neuropsychologi-
cal outcome. This finding is important because it empha-
sizes the relevant role of one early treatment target (nega-
tive symptom reduction) that may have especially
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decisive long-term benefits for neuropsychological
functioning in schizophrenia. It raises new questions for
future studies, including the differential benefit of vari-
ous treatments to said linkage between symptomatology
and cognitive performance, the replicability of this
effect in chronic patients with long courses of illness
and treatment, and the neurobiological mechanisms
through which treatment reduces negative symptoms to
enhance long-term neuropsychological outcome in
schizophrenia.
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